OptimizeRx Q4 revenue up 14% to $32.3M; FY2025 guidance at least $100M revenue

OptimizeRx Corp

Q4 revenue $32.3M (+14% YoY); gross profit $22.0M (+23% YoY, margin 68%).
GAAP net loss $(0.1)M in Q4; full-year GAAP net loss $(20.1)M or $(1.10)/share.
Non-GAAP net income $5.5M ($0.30 diluted) in Q4; Adj. EBITDA $8.8M (+53% YoY).
FY2025 guidance: revenue at least $100M, adjusted EBITDA at least $12M.
Net revenue retention 121% in 2024 vs 105% in 2023; 48 DAAP deals (up from 24).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.